Atara biotherapeutics announces fourth quarter and full year 2020 financial results and operational progress

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today reported financial results for the fourth quarter and full year 2020, recent business highlights and key catalysts over the next 18 months. “atara had a very strong year in 202
ATRA Ratings Summary
ATRA Quant Ranking